Latest Breaking News On - Eloxx pharmaceuticals inc - Page 16 : comparemela.com

Eloxx Pharmaceuticals (ELOX) Set to Announce Earnings on Friday

Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Rating) is scheduled to be issuing its quarterly earnings data on Friday, March 31st. Eloxx Pharmaceuticals Price Performance Shares of Eloxx Pharmaceuticals stock traded down $0.12 during trading hours on Thursday, reaching $2.35. The company’s stock had a trading volume of 673 shares, compared to its average volume of 128,304. […]

Earnings history for eloxx pharmaceuticalsExchange commissionEloxx pharmaceuticals incRenaissance technologiesEloxx pharmaceuticals company profileHedge funds weigh in on eloxx pharmaceuticalsEloxx pharmaceuticalsEloxx pharmaceuticals price performanceNews ratings for eloxx pharmaceuticals dailyGet ratingEloxx pharmaceuticals dailyNasdaq elox

Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013

Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Medialaureen cassidySumit aggarwalInvestorsjohn woolfordEloxx pharmaceuticals incEuropean commissionEloxx pharmaceuticalsDrug administrationInvestigational new drugDystrophic epidermolysis bullosaChief executive officerAdenomatous polyposis coliRibosome modulating agentsEukaryotic ribosome selective glycosidesFast trackOrphan drug designationPrivate securities litigation reform act

Eloxx Pharmaceuticals (ELOX) Announces Submission of IND Application for ZKN-013

Eloxx Pharmaceuticals (ELOX) Announces Submission of IND Application for ZKN-013
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sumit aggarwalDrug administrationEloxx pharmaceuticals incInvestigational new drugDystrophic epidermolysis bullosaChief executive officerAdenomatous polyposis coli

Eloxx Pharmaceuticals Announces Submission of

ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) Additional IND filing.

Sumit aggarwalJohn woolfordLaureen cassidyDrug administrationEloxx pharmaceuticals incEuropean commissionEloxx pharmaceuticalsInvestigational new drugDystrophic epidermolysis bullosaChief executive officerAdenomatous polyposis coliRibosome modulating agentsEukaryotic ribosome selective glycosidesFast trackOrphan drug designationPrivate securities litigation reform act

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

John woolfordLaureen cassidySumit aggarwalEloxx pharmaceuticals incDrug administrationEloxx pharmaceuticalsEuropean commissionInvestigational new drugDystrophic epidermolysis bullosaChief executive officerAdenomatous polyposis coliRibosome modulating agentsEukaryotic ribosome selective glycosidesFast trackOrphan drug designationPrivate securities litigation reform act